CN113993903A - 一种抗pd-1和pd-l1的四价双特异性抗体 - Google Patents

一种抗pd-1和pd-l1的四价双特异性抗体 Download PDF

Info

Publication number
CN113993903A
CN113993903A CN202180003496.6A CN202180003496A CN113993903A CN 113993903 A CN113993903 A CN 113993903A CN 202180003496 A CN202180003496 A CN 202180003496A CN 113993903 A CN113993903 A CN 113993903A
Authority
CN
China
Prior art keywords
cancer
antibody
pdl1
seq
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180003496.6A
Other languages
English (en)
Inventor
朱祯平
赵杰
黄浩旻
夏梦莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority to CN202210040098.8A priority Critical patent/CN114790242A/zh
Publication of CN113993903A publication Critical patent/CN113993903A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种结合人PD‑L1的抗体，以及基于所述的结合人PD‑L1的抗体构建的抗PD‑1和PD‑L1的四价双特异性抗体。所述四价双特异性抗体不需要进行Fc修饰，不会产生错配问题，制备方法简便，具有与单抗相似甚至更优的生物学活性和理化性质。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180003496.6A 2020-05-15 2021-04-19 一种抗pd-1和pd-l1的四价双特异性抗体 Pending CN113993903A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210040098.8A CN114790242A (zh) 2020-05-15 2021-04-19 一种结合人pd-l1的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/CN2020/090442 2020-05-15
PCT/CN2020/090442 WO2021226984A1 (zh) 2020-05-15 2020-05-15 一种抗pd-1和pd-l1的四价双特异性抗体
PCT/CN2021/088154 WO2021227782A1 (zh) 2020-05-15 2021-04-19 一种抗pd-1和pd-l1的四价双特异性抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210040098.8A Division CN114790242A (zh) 2020-05-15 2021-04-19 一种结合人pd-l1的抗体

Publications (1)

Publication Number Publication Date
CN113993903A true CN113993903A (zh) 2022-01-28

Family

ID=78525956

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210040098.8A Pending CN114790242A (zh) 2020-05-15 2021-04-19 一种结合人pd-l1的抗体
CN202180003496.6A Pending CN113993903A (zh) 2020-05-15 2021-04-19 一种抗pd-1和pd-l1的四价双特异性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210040098.8A Pending CN114790242A (zh) 2020-05-15 2021-04-19 一种结合人pd-l1的抗体

Country Status (6)

Country Link
US (1) US20230076124A1 (zh)
EP (2) EP4032913A1 (zh)
JP (2) JP7288984B2 (zh)
CN (2) CN114790242A (zh)
TW (2) TWI797609B (zh)
WO (2) WO2021226984A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199784A (zh) * 2021-11-30 2023-06-02 泽达生物医药有限公司 抗trop-2/pd-l1双特异性抗体
WO2023193767A1 (zh) * 2022-04-08 2023-10-12 上海济煜医药科技有限公司 一种抗原结合蛋白及其应用
CN114591438B (zh) * 2022-04-25 2023-12-05 达石药业(广东)有限公司 一种采用阳离子交换层析法纯化双特异性抗体的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2018001263A (es) * 2015-07-29 2018-04-13 Novartis Ag Nueva combinacion para el uso en el tratamiento del cancer.
EP3370768B9 (en) * 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
CN105461808B (zh) * 2015-12-24 2019-03-19 长春金赛药业股份有限公司 单克隆抗体及其应用
CU24613B1 (es) * 2016-02-06 2022-07-08 Epimab Biotherapeutics Inc Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr
WO2017215590A1 (en) * 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
CA3038504A1 (en) * 2016-10-14 2018-04-19 Dana-Farber Cancer Institute, Inc. Modular tetrameric bispecific antibody platform
CN108341871A (zh) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
KR101961871B1 (ko) * 2017-02-20 2019-07-17 주식회사 와이바이오로직스 신규 다중특이적 결합 단백질
SG10201913676QA (en) * 2017-04-01 2020-03-30 Beijing hanmi pharm co ltd Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CN109721657B (zh) * 2017-10-27 2021-11-02 北京比洋生物技术有限公司 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
JP7466459B2 (ja) * 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
CN112673093A (zh) * 2018-07-04 2021-04-16 赛通免疫治疗公司 靶向flt3、pd-1和/或pd-l1的免疫疗法的组合物和方法
CN113166269A (zh) * 2018-11-13 2021-07-23 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
CN113754775A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd-l1和her2的双特异性抗体
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd1×pdl1的双特异性抗体

Also Published As

Publication number Publication date
JP7397897B2 (ja) 2023-12-13
EP3964530A4 (en) 2023-01-18
CN114790242A (zh) 2022-07-26
TWI797609B (zh) 2023-04-01
EP4032913A1 (en) 2022-07-27
TW202221041A (zh) 2022-06-01
JP2022537256A (ja) 2022-08-25
WO2021226984A1 (zh) 2021-11-18
US20230076124A1 (en) 2023-03-09
EP3964530A1 (en) 2022-03-09
TW202144427A (zh) 2021-12-01
WO2021227782A1 (zh) 2021-11-18
JP7288984B2 (ja) 2023-06-08
JP2022120846A (ja) 2022-08-18

Similar Documents

Publication Publication Date Title
KR20210109520A (ko) 항체 및 이의 용도
KR20190117493A (ko) 항 pd-1 항체 및 그의 용도
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
EP4047018B1 (en) Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereof
US10696741B2 (en) Anti-IL-22R antibodies
EP4039704A1 (en) Anti-pd-1 antibody and use thereof
EP3647323A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2021244553A1 (zh) 一种抗pd-l1和egfr的四价双特异性抗体
US20220135686A1 (en) Antibody that binds to human pd-l1
CN113754773A (zh) 一种抗pd1×pdl1的双特异性抗体
CN113754771A (zh) 一种抗pdl1×egfr的双特异性抗体
CN114761434B (zh) Pd-1抗体及其制备方法与应用
EP4349867A1 (en) Specific binding protein targeting pd-l1 and cd73
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
CN116848144A (zh) 抗pd-l1抗体及其用途
CN114805590A (zh) 结合her2的双特异性抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066552

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination